<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78463</article-id><article-id pub-id-type="doi">10.7554/eLife.78463</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Structure of the IL-27 quaternary receptor signaling complex</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-272593"><name><surname>Caveney</surname><given-names>Nathanael A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4828-3479</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-273508"><name><surname>Glassman</surname><given-names>Caleb R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3342-7989</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-89367"><name><surname>Jude</surname><given-names>Kevin M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3675-5136</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-107198"><name><surname>Tsutsumi</surname><given-names>Naotaka</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3617-7145</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-6833"><name><surname>Garcia</surname><given-names>K Christopher</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9273-0278</contrib-id><email>kcgarcia@stanford.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Department of Molecular and Cellular Physiology, Stanford University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Program in Immunology, Stanford University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006w34k90</institution-id><institution>Howard Hughes Medical Institute, Stanford University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kruse</surname><given-names>Andrew C</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard Medical School</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>17</day><month>05</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e78463</elocation-id><history><date date-type="received" iso-8601-date="2022-03-08"><day>08</day><month>03</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-05-16"><day>16</day><month>05</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-03-09"><day>09</day><month>03</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.03.08.483525"/></event></pub-history><permissions><copyright-statement>© 2022, Caveney, Glassman et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Caveney, Glassman et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-78463-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-78463-figures-v2.pdf"/><abstract><p>Interleukin 27 (IL-27) is a heterodimeric cytokine that functions to constrain T cell-mediated inflammation and plays an important role in immune homeostasis. Binding of IL-27 to cell surface receptors, IL-27Rα and gp130, results in activation of receptor-associated Janus Kinases and nuclear translocation of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT3 transcription factors. Despite the emerging therapeutic importance of this cytokine axis in cancer and autoimmunity, a molecular blueprint of the IL-27 receptor signaling complex, and its relation to other gp130/IL-12 family cytokines, is currently unclear. We used cryogenic-electron microscopy to determine the quaternary structure of IL-27, composed of p28 and Epstein-Barr Virus-Induced 3 (Ebi3) subunits, bound to receptors, IL-27Rα and gp130. The resulting 3.47 Å resolution structure revealed a three-site assembly mechanism nucleated by the central p28 subunit of the cytokine. The overall topology and molecular details of this binding are reminiscent of IL-6 but distinct from related heterodimeric cytokines IL-12 and IL-23. These results indicate distinct receptor assembly mechanisms used by heterodimeric cytokines with important consequences for targeted agonism and antagonism of IL-27 signaling.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cytokine</kwd><kwd>signaling</kwd><kwd>receptors</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Caveney</surname><given-names>Nathanael A</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Garcia</surname><given-names>K Christopher</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01-AI51321</award-id><principal-award-recipient><name><surname>Garcia</surname><given-names>K Christopher</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The cryogenic-electron microscopy structure of IL-27 bound to receptors, IL-27Rα and gp130, revealing a three-site assembly mechanism and overall topology and molecular details reminiscent of IL-6 but distinct from related IL-12 and IL-23.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Cytokines are secreted factors that mediate cell-cell communication in the immune system (<xref ref-type="bibr" rid="bib34">Spangler et al., 2015</xref>). Binding of cytokines to cell surface receptors, in most cases, leads to activation of receptor-associated Janus Kinase (JAK) proteins, which phosphorylate each other as well as downstream Signal Transducer and Activator of Transcription (STAT) proteins, triggering nuclear translocation and regulation of gene expression. Cytokines can be classified by their use of shared receptors which transduce signals for multiple cytokines within a family. Interleukin-6 signal transducer (IL-6ST), also known as glycoprotein 130 (gp130), is a shared receptor that mediates signaling of multiple cytokines including IL-6, IL-11, and IL-27. Unlike other gp130 family cytokines, IL-27 is a heterodimeric cytokine consisting of a four-helix bundle, IL-27p28 (p28), with similarity to IL-6, complexed with a secreted binding protein, Epstein-Barr Virus-Induced 3 (Ebi3), with homology to type I cytokine receptors (<xref ref-type="bibr" rid="bib26">Pflanz et al., 2002</xref>). IL-27 signals through a receptor complex consisting of IL-27Rα (TCCR/WSX-1) and gp130 expressed on T cells, NK cells, monocytes, dendritic cells, B cells as well as subsets of endothelial and epithelial cells (<xref ref-type="bibr" rid="bib26">Pflanz et al., 2002</xref>; <xref ref-type="bibr" rid="bib27">Pflanz et al., 2004</xref>; <xref ref-type="bibr" rid="bib16">Heng et al., 2008</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). Binding of IL-27 to its receptor subunits triggers the activation of receptor-associated JAK1 and JAK2 leading to phosphorylation of STAT1 and STAT3 (<xref ref-type="bibr" rid="bib20">Lucas et al., 2003</xref>; <xref ref-type="bibr" rid="bib23">Owaki et al., 2008</xref>; <xref ref-type="bibr" rid="bib43">Wilmes et al., 2021</xref>). Functionally, IL-27 signaling serves to constrain inflammation by antagonizing differentiation of pro-inflammatory Th17 cells (<xref ref-type="bibr" rid="bib35">Stumhofer et al., 2006</xref>), stimulating T-bet expression in regulatory T cells (Tregs) (<xref ref-type="bibr" rid="bib14">Hall et al., 2012</xref>), and inducing production of the anti-inflammatory cytokine IL-10 (<xref ref-type="bibr" rid="bib36">Stumhofer et al., 2007</xref>). The important role of IL-27 in constraining inflammation has prompted the development of antagonist antibodies, one of which is currently being developed as a cancer immunotherapy (<xref ref-type="bibr" rid="bib24">Patnaik et al., 2021</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Composition and cryogenic-electron microscopy (cryoEM) structure of human interleukin 27 (IL-27) quaternary complex.</title><p>(<bold>A</bold>) Cartoon representation of the components of the IL-27 quaternary signaling complex. gp130 (red), p28 (blue), Epstein-Barr Virus-Induced 3 (Ebi3; purple), IL-27Rα (green), with domains excluded from the imaged constructs in gray. The D1 Ig domain of gp130 is represented by red, with an additional dark red outline to distinguish it from FNIII domains in gp130, Ebi3, and IL-27Rα. (<bold>B</bold>) Reference-free 2D averages from cryoEM of the IL-27 quaternary complex. (<bold>C</bold>) Refined and sharpened cryoEM density maps of IL-27 quaternary complex, colored as in (<bold>A</bold>). (<bold>D</bold>) Ribbon representation of the atomistic modeling of IL-27 quaternary complex, colored as in (<bold>A</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-78463-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Interleukin 27 (IL-27) quaternary complex cryogenic-electron microscopy (cryoEM) data processing.</title><p>(<bold>A</bold>) Workflow for cryoEM data processing. Representative micrograph, reference free 2D averages, and cryoEM maps at the various stages of processing. Depicted maps were z-flipped prior to model building. (<bold>B</bold>) Local resolution estimation of the finalized cryoEM map of IL-27 quaternary complex (<xref ref-type="bibr" rid="bib29">Punjani et al., 2017</xref>). (<bold>C</bold>) FSC curve of the IL-27 quaternary complex reconstruction using gold-standard refinement calculated from unmasked and masked half maps. (<bold>D</bold>) Orientational distribution of the IL-27 quaternary complex reconstruction. (<bold>E</bold>) Representative cryoEM density regions of p28, IL-27Rα, Epstein-Barr Virus-Induced 3 (Ebi3), and gp130.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-78463-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Distances and constraints of the Ebi3-gp130 GS-linker.</title><p>38 Å separate resolved residues at the C-terminus of p28 and the N-terminus of gp130; a distance easily accommodated by the 20 a.a. GS linker and unresolved residues (~110 Å).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-78463-fig1-figsupp2-v2.tif"/></fig></fig-group><p>Although IL-27 is a member of the gp130 family, its heterodimeric composition is similar to IL-12 and IL-23, which are cytokines that share a p40 subunit analogous to Ebi3. In this system, the p40 subunit of IL-12 and IL-23 directly engages the shared receptor IL-12Rβ1 in a manner distinct from IL-6 and related cytokines (<xref ref-type="bibr" rid="bib12">Glassman et al., 2021a</xref>). Given the diverse receptor assembly mechanisms used by cytokine receptors, we sought to determine the structure of IL-27 in complex with its signaling receptors, gp130 and IL-27Rα, by cryoEM.</p><p>Here we report the 3.47 Å resolution structure of the complete IL-27 receptor complex. In this structure, the central IL-27 cytokine engages IL-27Rα through a composite interface consisting of p28 and the D2 domain of Ebi3. A conserved tryptophan residue at the tip of p28 then engages the D1 domain of gp130 to facilitate quaternary complex assembly. This receptor assembly mechanism bears striking resemblance to that of IL-6 but is distinct from IL-12 and IL-23, indicating divergent receptor binding modes for heterodimeric cytokines.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>CryoEM structure of the IL-27 quaternary complex</title><p>Interleukin 27 (p28/Ebi3) signals through a receptor complex composed of IL-27Rα and the shared receptor gp130 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The extracellular domain of IL-27Rα consists of five fibronectin type III (FNIII) domains (D1–5) of which the N-terminal D1–D2 constitute a cytokine-binding homology region (CHR). gp130 has a similar domain architecture but with the addition of an N-terminal immunoglobin (Ig) domain (D1). Initial attempts at reconstituting a soluble receptor complex through mixing of IL-27, IL-27Rɑ D1–D2, and gp130 D1–D3 resulted in dissociation on size-exclusion chromatography due to the low affinity of gp130. To stabilize the complex, we expressed p28 fused to gp130 through a long (20 a.a.) flexible linker which enabled us to purify the complete IL-27 receptor complex by size exclusion chromatography. Importantly, the long linker did not constrain the binding mode, with ~110 Å of unresolved residues spanning a distance of 38 Å between termini (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), but rather raised the effective concentration of gp130. The complex was vitrified and subject to single-particle cryoEM analysis. The quaternary complex was determined to a resolution of 3.47 Å (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="table" rid="table1">Table 1</xref>). All domains of IL-27 and IL-27Rα, as well as D1 of gp130 had well resolved cryoEM density (<xref ref-type="fig" rid="fig1">Figure 1B-C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>), with local resolution estimates near and exceeding 3 Å in this region (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). The local resolution for the D2 density of gp130 is lower, yet able to be built with confidence, while D3 density was interpretable for domain placement (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>CryoEM data collection, refinement, and validation statistics.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="center" valign="bottom">IL-27 Complex (PDB 7U7N/EMD-26382)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Data collection and processing</bold></td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Magnification</td><td align="center" valign="bottom">105,000</td></tr><tr><td align="left" valign="bottom">Voltage (keV)</td><td align="center" valign="bottom">300</td></tr><tr><td align="left" valign="bottom">Electron exposure (e<sup>-</sup>/Å<sup>2</sup>)</td><td align="center" valign="bottom">60</td></tr><tr><td align="left" valign="bottom">Defocus range (µm)</td><td align="center" valign="bottom">–0.8 to –2.0</td></tr><tr><td align="left" valign="bottom">Pixel size (Å)</td><td align="center" valign="bottom">0.839</td></tr><tr><td align="left" valign="bottom">Symmetry imposed</td><td align="center" valign="bottom">C1</td></tr><tr><td align="left" valign="bottom">Initial particle images</td><td align="center" valign="bottom">6,387,370</td></tr><tr><td align="left" valign="bottom">Final particle images</td><td align="center" valign="bottom">548,147</td></tr><tr><td align="left" valign="bottom">Map resolution FSC threshold (Å)</td><td align="center" valign="bottom">0.143</td></tr><tr><td align="left" valign="bottom">Map resolution (Å)</td><td align="center" valign="bottom">3.47</td></tr><tr><td align="left" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>Refinement</bold></td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">Initial model used (PDB)</td><td align="center" valign="bottom">AlphaFold</td></tr><tr><td align="left" valign="bottom">Model resolution FSC threshold (Å)</td><td align="center" valign="bottom">0.143</td></tr><tr><td align="left" valign="bottom">Model resolution (Å)</td><td align="center" valign="bottom">1.9</td></tr><tr><td align="left" valign="bottom">Map sharpening <italic>B</italic>-factor (Å<sup>2</sup>)</td><td align="center" valign="bottom">189.6</td></tr><tr><td align="left" valign="bottom">Model Composition</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Non-hydrogen atoms</td><td align="center" valign="bottom">7,284</td></tr><tr><td align="left" valign="bottom"> Protein residues</td><td align="center" valign="bottom">884</td></tr><tr><td align="left" valign="bottom"> Ligands</td><td align="center" valign="bottom">16</td></tr><tr><td align="left" valign="bottom"><italic>B</italic>-factors (Å<sup>2</sup>)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Protein</td><td align="center" valign="bottom">102.97</td></tr><tr><td align="left" valign="bottom"> Ligand</td><td align="center" valign="bottom">114.62</td></tr><tr><td align="left" valign="bottom">R.m.s. deviations</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Bond lengths (Å)</td><td align="center" valign="bottom">0.003</td></tr><tr><td align="left" valign="bottom"> Bond angles (°)</td><td align="center" valign="bottom">0.610</td></tr><tr><td align="left" valign="bottom">Validation</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom"> MolProbity score</td><td align="center" valign="bottom">1.60</td></tr><tr><td align="left" valign="bottom"> Clashscore</td><td align="center" valign="bottom">8.81</td></tr><tr><td align="left" valign="bottom"> EMringer score</td><td align="center" valign="bottom">2.33</td></tr><tr><td align="left" valign="bottom"> Rotamer outliers (%)</td><td align="center" valign="bottom">0.89</td></tr><tr><td align="left" valign="bottom"> Ramachandran plot</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">  Favored (%)</td><td align="center" valign="bottom">97.37</td></tr><tr><td align="left" valign="bottom">  Allowed (%)</td><td align="center" valign="bottom">2.63</td></tr><tr><td align="left" valign="bottom">  Outliers (%)</td><td align="center" valign="bottom">0.00</td></tr></tbody></table></table-wrap><p>The IL-27 quaternary complex exhibits a molecular architecture containing ‘sites 1–3’, as seen in other gp130 family cytokines (<xref ref-type="bibr" rid="bib4">Boulanger et al., 2003</xref>) and as hypothesized previously (<xref ref-type="bibr" rid="bib33">Skiniotis et al., 2008</xref>; <xref ref-type="fig" rid="fig1">Figure 1D</xref>). In this structure, IL-27 bridges IL-27Rα and gp130 to initiate downstream signaling through JAK1 and JAK2 (<xref ref-type="bibr" rid="bib9">Ferrao et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Pradhan et al., 2010</xref>). Within IL-27, the four-helical bundle of p28 packs against the hinge between Ebi3 D1 and D2 in a site 1 interaction. Opposite Ebi3, IL-27Rα D1-D2 engages the helical face of p28 in an interaction stabilized by stem contact between the D2 domains of IL-27Rα and Ebi3 to form a site 2 interaction. On the posterior face of IL-27, the D1 domain of gp130 binds to a conserved tryptophan at the tip of p28 to make a classical site 3 interaction (<xref ref-type="bibr" rid="bib4">Boulanger et al., 2003</xref>).</p></sec><sec id="s2-2"><title>Site 1–3 interface architecture of the IL-27 quaternary complex</title><p>A site 1 interface between p28 and Ebi3 is used to form the heterodimeric cytokine IL-27. In this interaction, the alpha helices A and D, the AB loop, and the C-terminus of p28 pack tightly against the hinge region between D1 and D2 of Ebi3 (<xref ref-type="fig" rid="fig2">Figure 2A, B</xref>). This interaction is mediated by a variety of hydrogen bonds between p28 and the hinge region of Ebi3, particularly along alpha helices A and D of p28. At the center of this interface is p28 R219 which is coordinated by D207 and T209 in Ebi3. Extending from this region, a hydrophobic patch of residues on the C-terminus and AB loop of p28 (F94, W97, L223, W232) packs against residues in the Ebi3 hinge (F97, F157, I160). The extensive and hydrophobic nature of this interface is consistent with the observation that co-expression of p28 and Ebi3 is required for efficient cytokine secretion (<xref ref-type="bibr" rid="bib26">Pflanz et al., 2002</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Binding interfaces of the human interleukin 27 (IL-27) quaternary complex.</title><p>(<bold>A</bold>) Ribbon representation of the IL-27 quaternary signaling complex, containing gp130 (red), p28 (blue), Epstein-Barr Virus-Induced 3 (Ebi3; purple), and IL-27Rα (green). Regions containing sites 1, 2, and 3 are boxed in purple, green, and red, respectively. (<bold>B</bold>) Two views of the site 1 interface, colored as in (<bold>A</bold>). (<bold>C</bold>) The site 2 interface, composed of a site 2a, p28 to IL-27Rα, interaction, and a site 2b, Ebi3 to IL-27Rα, interaction. All proteins are colored as in (<bold>A</bold>). (<bold>D,E</bold>) The site 3 interface, composed of a site 3a, p28 to gp130, interaction, and a site 3b, Ebi3 to IL-27Rα, interaction. All proteins are colored as in (<bold>A</bold>). (<bold>F</bold>) Structural overlay of site 3 interacting domains from IL-27 complex, IL-6 complex (PDB 1P9M), and viral IL-6 (vIL-6) complex (PDB 1L1R). IL-27 quaternary complex colored as in (<bold>A</bold>), IL-6 ternary complex in orange (IL-6) and yellow (gp130), and vIL-6 binary complex in green (vIL-6) and teal (gp130).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-78463-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Cryogenic-electron microscopy (CryoEM) density of binding interfaces of the human IL-27 quaternary complex.</title><p>(<bold>A</bold>) Ribbon representation of the IL-27 quaternary signaling complex, containing gp130 (red), p28 (blue), Epstein-Barr Virus-Induced 3 (Ebi3; purple), and IL-27Rα (green). Regions containing sites 1, 2, and 3 are boxed in purple, green, and red, respectively. (<bold>B</bold>) CryoEM density of the site 1 interaction. Colored as in (<bold>A</bold>). (<bold>C</bold>) CryoEM density of the site 2 interaction. Colored as in (<bold>A</bold>). (<bold>D</bold>) CryoEM density of the site 3 interaction. Colored as in (<bold>A</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-78463-fig2-figsupp1-v2.tif"/></fig></fig-group><p>Opposing the Ebi3-binding site, p28 engages the hinge region of IL-27Rα (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, site 2 a). This interaction is stabilized by stem-stem contacts between the D2 domains of IL-27Rα and Ebi3 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, site 2b). Alpha helices A and C of p28 form the bulk of the site 2a interaction. In contrast to the site 1 interaction which forms the holo-cytokine, the site 2a interaction is more limited both in terms of hydrophobicity and buried surface area (Site 1: 1,339.4 Å<sup>2</sup>, Site 2a: 810.4 Å<sup>2</sup>) (<xref ref-type="bibr" rid="bib19">Krissinel and Henrick, 2007</xref>). One notable feature of this interface is the contribution of a 13 amino acid polyglutamic acid region in p28. This region is not well resolved in the cryoEM density, but may form an alpha helix (polyE helix) and contact R74 and K77 in the IL-27Rɑ D1 domain. Cytokine binding is stabilized by ‘stem-stem’ interactions between D2 FNIII domains of IL-27Rα and Ebi3. This site 2b interaction is characterized by a high degree of shape and charge complementarity with an arginine-rich patch of Ebi3 (R143, R171, R194) packing against the positively charged base of IL-27Rɑ D2 domain (D138, D142, E146). The composite nature of IL-27Rɑ binding explains, in part, the inability of p28 to mediate IL-27 signaling in the absence of Ebi3 (<xref ref-type="bibr" rid="bib37">Stumhofer et al., 2010</xref>).</p><p>On the posterior face of the cytokine, a classical site 3 interface is formed through the interaction of the D1 Ig domain of gp130 associating with both p28 (site 3a) and Ebi3 (site 3b) (<xref ref-type="fig" rid="fig2">Figure 2D, E</xref>). Similar to IL-12 family members, IL-23 and IL-12 (<xref ref-type="bibr" rid="bib12">Glassman et al., 2021a</xref>), and the gp130 family members IL-6 (<xref ref-type="bibr" rid="bib4">Boulanger et al., 2003</xref>) and viral IL-6 (<xref ref-type="bibr" rid="bib6">Chow et al., 2001</xref>), this interaction is anchored by the conserved W197 on p28 which packs tightly against the base of the D1 Ig domain of gp130 (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). The site 3 interaction is extended by the AB loop of p28 which contacts both gp130 and Ebi3. We do not observe an interaction between the N-terminus of gp130 and helix D of the four-helix bundle as observed for other site 3 interactions; however, this may be due to the use of a flexible GS linker which connects p28 to gp130. The tip of gp130 D1 packs against the top of Ebi3 D1 in a limited interface centered around Ebi3 F118.</p><p>The heterodimeric nature of IL-27 has led some to classify it as an IL-12 family cytokine (<xref ref-type="bibr" rid="bib39">Trinchieri et al., 2003</xref>). However, comparison of the IL-27 receptor complex with that of IL-23 and IL-12 reveals striking differences (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref>). In IL-27, the central p28 subunit engages all receptor components. In contrast, each subunit of IL-23 and IL-12 engages a different receptor in a modular interaction mechanism (<xref ref-type="bibr" rid="bib12">Glassman et al., 2021a</xref>). The assembly of IL-27 more closely resembles that of IL-6, in which the central four-helix bundle encodes binding sites for all receptor components (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). However, in the case of IL-6, this motif is duplicated through a C2 symmetry axis due to a dual role of gp130 at site 2 and site 3. The similarity between IL-27 and IL-6 is observed not only in overall architecture but also in molecular detail, where IL-6, vIL-6, and IL-27 all engage gp130 using a highly convergent interface in which a tryptophan from helix D of the cytokine (W197 in p28, W185 in IL-6, W166 in vIL-6) forms an aromatic anchor that is capped by Y116 of gp130 (<xref ref-type="fig" rid="fig2">Figures 2F</xref> and <xref ref-type="fig" rid="fig3">3D, E</xref>). Alignment of gp130 D1–(v)IL-6 pairs to the IL-27 structure reveals a tight correlation in gp130 binding pose with Cα RMSDs of 1.039 Å (IL-6) and 1.015 Å (vIL-6) across 149 and 124 trimmed residue pairs. This striking convergence of gp130 binding modes helps to explain the ability of p28 to antagonize IL-6 signaling (<xref ref-type="bibr" rid="bib37">Stumhofer et al., 2010</xref>) and contextualizes its place in respect to both gp130 and IL-12 family cytokines.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Comparison of IL-27 to IL-12 and IL-6 family complexes.</title><p>(<bold>A</bold>) Ribbon representation of the IL-27 signaling complex, containing gp130 (red), p28 (blue), Epstein-Barr Virus-Induced 3 (Ebi3; purple), and IL-27Rα (green). Sites 1, 2, and 3 are noted with a numbered circle. (<bold>B</bold>) Ribbon representation of the IL-23 signaling complex (IL-12 family), containing IL-23R (red), IL-23p19 (blue), p40 (purple), and IL-12Rβ1 (green) (PDB 6WDQ). Sites 1 and 3 are noted as in (<bold>A</bold>), with the unoccupied site 2 marked with a gray ‘X’ and the distinct IL-12/IL-23 site 2 marked with a circled number 2. (<bold>C</bold>) Ribbon representation of a model of the IL-12 signaling complex (IL-12 family), containing IL-12Rβ2 (red), IL-12p35 (blue), p40 (purple), and IL-12Rβ1 (green) (<xref ref-type="bibr" rid="bib2">Baek et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Glassman et al., 2021a</xref>). Sites 1 and 3 are noted as in (<bold>A</bold>), with the unoccupied site 2 marked with a gray ‘X’ and the distinct IL-12/IL-23 site 2 marked with a circled number 2. (<bold>D</bold>) Ribbon representation of the IL-6 signaling complex (IL-6 family), containing gp130 (red and green), IL-6 (blue), and IL-6Rα (purple) (PDB 1P9M). Secondary copies of each protein in the complex are colored in white. Sites 1, 2, and 3 are noted as in (<bold>A</bold>). (<bold>E</bold>) Ribbon representation of the viral IL-6 signaling complex (IL-6 family), containing gp130 (red and green) and (blue) (PDB 1I1R). Secondary copies of each protein in the complex are colored in white. Sites 2 and 3 are noted as in (<bold>A</bold>), with the unoccupied site 1 marked with a gray ‘X’.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-78463-fig3-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>A key paradigm in cytokine structural biology is the use of shared receptor components that mediate diverse signaling outputs. IL-27 extends this, given that it shares the gp130 subunit with IL-6 but mediates distinct and often countervailing functional effects. Here we find that IL-27 assembles a receptor complex reminiscent of IL-6 but distinct from other heterodimeric IL-12/23 class cytokines. Interestingly, the soluble form of IL-6Rα (sIL-6Rα) generated through alternative splicing or proteolytic cleavage can complex with IL-6 to potentiate signaling in gp130-expressing cells (<xref ref-type="bibr" rid="bib18">Kishimoto and Kang, 2022</xref>). This IL-6/sIL-6Rα complex thus may be functionally analogous to heterodimeric cytokine IL-27, albeit with gp130 playing the role of both site 2 and 3 receptors in the case of IL-6/sIL-6Rα signalling, allowing for broader range of cells which can be stimulated.</p><p>In addition to their roles in IL-27 signaling, p28 and Ebi3 have been implicated in the assembly of alternate cytokine complexes. Ebi3 has been reported to complex with the p35 subunit of IL-12 to form IL-35 (<xref ref-type="bibr" rid="bib7">Collison et al., 2007</xref>) and the p19 subunit of IL-23 to form IL-39 (<xref ref-type="bibr" rid="bib42">Wang et al., 2016</xref>), while p28 has been proposed to interact with IL-6Rα (<xref ref-type="bibr" rid="bib11">Garbers et al., 2013</xref>) and the p40 subunit of IL-12/23 (<xref ref-type="bibr" rid="bib41">Wang et al., 2012</xref>). These results suggest structural plasticity among heterodimeric cytokines; however, additional work is needed to characterize the physiological relevance and biochemical basis for these cytokines.</p><p>As in other types of cytokine signaling, there is context-dependent therapeutic potential in both the inhibition and potentiation of IL-27 signaling. The targeting of the heterodimeric cytokines of the IL-12 family has been well explored, with various clinically approved inhibitors, targeting either IL-23 signaling via p19 (Risankizumab, Guselkumab, Tildrakizumab) (<xref ref-type="bibr" rid="bib38">Tait Wojno et al., 2019</xref>) or IL-12 and IL-23 signaling via the shared p40 (Ustekinumab) (<xref ref-type="bibr" rid="bib21">Luo et al., 2010</xref>). In these cases, the inhibition of IL-12 family members antagonizes the pro-inflammatory effects of these cytokines. Due to the role of IL-27 in the regulation T cell-mediated inflammation (<xref ref-type="bibr" rid="bib38">Tait Wojno et al., 2019</xref>), inhibition of IL-27 is currently being explored for its use in the inhibition of aberrant IL-27 signaling in cancer (<xref ref-type="bibr" rid="bib24">Patnaik et al., 2021</xref>). The structure of the IL-27 quaternary signaling complex provides ample opportunities for the design of IL-27 inhibitors targeting different steps in receptor assembly to better regulate IL-27 signaling.</p><p>On the other end of the spectrum, IL-27 agonism has been explored for its therapeutic use in inflammatory autoimmune dysregulation such as experimental autoimmune encephalomyelitis (<xref ref-type="bibr" rid="bib10">Fitzgerald et al., 2013</xref>) and colitis (<xref ref-type="bibr" rid="bib15">Hanson et al., 2014</xref>). Despite the promise of IL-27 as a therapeutic, the bipartite nature of IL-27 limits its usefulness in the clinic. Using the interfacial information provided in the structure of the IL-27 quaternary complex, structure-guided protein engineering techniques can now be used to improve the therapeutic potential of IL-27. One such application may be to generate single agent IL-27 agonists by affinity maturing the interactions between p28 and its receptor subunit, as has been done recently to generate IL-6 which do not require IL-6Rα binding for efficient signaling (<xref ref-type="bibr" rid="bib22">Martinez-Fabregas et al., 2019</xref>). Conversely, attenuating the affinity of p28 for IL-27Rα might be used to generate cell-type biased partial agonists with selective activity based on differences in IL-27Rα expression across cell-type and activation state (<xref ref-type="bibr" rid="bib40">Villarino et al., 2005</xref>) as has been done for IL-2 (<xref ref-type="bibr" rid="bib13">Glassman et al., 2021b</xref>), IL-10 (<xref ref-type="bibr" rid="bib32">Saxton et al., 2021</xref>), and IL-12 (<xref ref-type="bibr" rid="bib12">Glassman et al., 2021a</xref>).</p><p>Resolution of the complete IL-27 receptor complex reveals how this therapeutically important cytokine engages its receptor subunits. The receptor assembly mechanism bears striking resemblance to that of IL-6 but is distinct from IL-12 and IL-23, indicating divergent receptor binding modes for heterodimeric cytokines. This structural insight further paves the way for the continued development of therapeutics that modulate IL-27 signaling.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Human embryonic kidney cells</td><td align="left" valign="bottom">GIBCO</td><td align="left" valign="bottom">Expi293</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pD649-IL-27Rα (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See: Methods - Cloning and protein expression</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pD649-Ebi3 (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See: Methods - Cloning and protein expression</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pD649-p28-gp130 (plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See: Methods - Cloning and protein expression</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Data collection software</td><td align="left" valign="bottom">SerialEM</td><td align="left" valign="bottom">SerialEM</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Data processing software</td><td align="left" valign="bottom">Structura Biotechnology Inc.</td><td align="left" valign="bottom">cryoSPARC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Data sharpening software</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Sanchez-Garcia et al., 2021</xref></td><td align="left" valign="bottom">DeepEMhancer</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Initial modeling software</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib17">Jumper et al., 2021</xref></td><td align="left" valign="bottom">AlphaFold</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Graphics software</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Pettersen et al., 2021</xref></td><td align="left" valign="bottom">UCSF ChimeraX</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Modeling and refinement software</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref></td><td align="left" valign="bottom">Phenix</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Modeling and refinement software</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib8">Emsley and Cowtan, 2004</xref></td><td align="left" valign="bottom">Coot</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Model validation software</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib3">Barad et al., 2015</xref></td><td align="left" valign="bottom">EMRinger</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Model validation software</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib5">Chen et al., 2010</xref></td><td align="left" valign="bottom">MolProbity</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cloning and protein expression</title><p>Human IL-27Rα (D1-D2, residues 36–231), Ebi3 (residues 21–228), and p28 (residues 29–243)-(GGGGS)<sub>4</sub>-gp130 (D1-D3, residues 23–321) were cloned into the expression vector pD649. All components were expressed with signal sequence of influenza hemagglutinin and IL-27Rα and Ebi3 contained C-terminal 6-His tags for affinity purification. Proteins were co-expressed in Expi293F cells (GIBCO) maintained in Expi293 Expression Media (GIBCO) at 37 °C with 5% CO<sub>2</sub> and gentle agitation.</p><sec id="s4-1-1"><title>Material availability</title><p>The expression plasmids for the IL-27 complex are available from KCG (<ext-link ext-link-type="uri" xlink:href="https://kcgarcia@stanford.edu">https://kcgarcia@stanford.edu</ext-link>) by request.</p></sec></sec><sec id="s4-2"><title>Protein purification</title><p>IL-27 quaternary complex was purified by Ni-NTA chromatography followed by size exclusion chromatography with a Superdex 200 column (GE Lifesciences). Fractions containing pure IL-27 complex were pooled and stored at 4°C until vitrification.</p></sec><sec id="s4-3"><title>Cryo-electron microscopy</title><p>Aliquots of 3 μL of IL-27 quaternary complex were applied to glow-discharged Quantifoil (1.2/1.3) grids. The grids were blotted for 3 s at 100% humidity with an offset of 3 and plunge frozen into liquid ethane using a Vitrobot Mark IV (Thermo Fisher). Grid screening and preliminary dataset collection occurred at Stanford cEMc. Final grids were imaged on a 300 kV FEI Titan Krios microscope (Thermo Fisher) located at the HHMI Janelia Research Campus and equipped with a K3 camera and energy filter (Gatan). Movies were collected at a magnification of ×105,000, corresponding to a 0.839 Å per physical pixel. The dose was set to a total of 50 electrons per Å<sup>2</sup> over an exposure of 50 frames. Automated data collection was carried out using SerialEM with a nominal defocus range set from –0.8 to –2.0 μM. 18,168 movies were collected.</p></sec><sec id="s4-4"><title>Image processing</title><p>All processing was performed in cryoSPARC (<xref ref-type="bibr" rid="bib29">Punjani et al., 2017</xref>) unless otherwise noted (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). The 18,168 movies were motion corrected using patch motion correction and micrographs were binned to 0.839 Å per pixel. The contrast transfer functions (CTFs) of the flattened micrographs were determined using patch CTF and 6,387,370 particles were picked using blob picking and subsequently template picking. A subset of 2,008,987 particles were used in reference-free 2D classification. A particle stack containing 109,536 2D cleaned particles was used to generate three ab initio models, one of which resembled a complete complex. This ab initio model was then used against two junk classes in six rounds of iterative heterogenous refinement to reduce the full particle stack to 548,147 particles. These particles were refined using cryoSPARC non-uniform refinement (<xref ref-type="bibr" rid="bib30">Punjani et al., 2020</xref>) followed by local refinement with a mask excluding gp130 D3 domain to achieve a resolution of 3.47 Å. Resolution was determined at a criterion of 0.143 Fourier shell correlation gold-standard refinement procedure. The final map was sharpened using deepEMhancer (<xref ref-type="bibr" rid="bib31">Sanchez-Garcia et al., 2021</xref>).</p></sec><sec id="s4-5"><title>Model building and refinement</title><p>AlphaFold models (<xref ref-type="bibr" rid="bib17">Jumper et al., 2021</xref>) of IL-27Rα, Ebi3, p28, and gp130 were docked into the map using UCSF Chimera X (<xref ref-type="bibr" rid="bib25">Pettersen et al., 2021</xref>). The resultant model was then refined using Phenix real space refine (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>) and manual building in Coot (<xref ref-type="bibr" rid="bib8">Emsley and Cowtan, 2004</xref>). The final model fit the map well (EMRinger [<xref ref-type="bibr" rid="bib3">Barad et al., 2015</xref>] score 2.33) and produced a favorable MolProbity score of 1.60 (<xref ref-type="bibr" rid="bib5">Chen et al., 2010</xref>) with side-chain rotamers occupying 97.37% Ramachandran favored and 0.00% outliers (<xref ref-type="table" rid="table1">Table 1</xref>).</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>is the founder of Synthekine</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Funding acquisition, Project administration, Supervision, Writing – review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-78463-mdarchecklist1-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>CryoEM maps and atomic coordinates for human IL-27 quaternary complex have been deposited in the EMDB (EMD- 26382) and PDB (7U7N) respectively.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Caveney</surname><given-names>NA</given-names></name><name><surname>Glassman</surname><given-names>CR</given-names></name><name><surname>Jude</surname><given-names>KM</given-names></name><name><surname>Tsutsumi</surname><given-names>N</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>IL-27 quaternary receptor signaling complex</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7U7N">7U7N</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Caveney</surname><given-names>NA</given-names></name><name><surname>Glassman</surname><given-names>CR</given-names></name><name><surname>Jude</surname><given-names>KM</given-names></name><name><surname>Tsutsumi</surname><given-names>N</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>IL-27 quaternary receptor signaling complex</data-title><source>Electron Microscopy Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/emdb/EMD-26382">EMD-26382</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Rui Yan at the HHMI Janelia CryoEM Facility for help in microscope operation and final data collection. We thank Liz Montabana and Stanford cEMc for microscope access for preliminary data collection. NAC is a CIHR postdoctoral fellow. KCG is an investigator with the Howard Hughes Medical Institute. KCG is supported by National Institutes of Health grant R01-AI51321, the Mathers Foundation, and the Ludwig Foundation.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Davis</surname><given-names>IW</given-names></name><name><surname>Echols</surname><given-names>N</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Hung</surname><given-names>L-W</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Oeffner</surname><given-names>R</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Zwart</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>M</given-names></name><name><surname>DiMaio</surname><given-names>F</given-names></name><name><surname>Anishchenko</surname><given-names>I</given-names></name><name><surname>Dauparas</surname><given-names>J</given-names></name><name><surname>Ovchinnikov</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>GR</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cong</surname><given-names>Q</given-names></name><name><surname>Kinch</surname><given-names>LN</given-names></name><name><surname>Schaeffer</surname><given-names>RD</given-names></name><name><surname>Millán</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Adams</surname><given-names>C</given-names></name><name><surname>Glassman</surname><given-names>CR</given-names></name><name><surname>DeGiovanni</surname><given-names>A</given-names></name><name><surname>Pereira</surname><given-names>JH</given-names></name><name><surname>Rodrigues</surname><given-names>AV</given-names></name><name><surname>van Dijk</surname><given-names>AA</given-names></name><name><surname>Ebrecht</surname><given-names>AC</given-names></name><name><surname>Opperman</surname><given-names>DJ</given-names></name><name><surname>Sagmeister</surname><given-names>T</given-names></name><name><surname>Buhlheller</surname><given-names>C</given-names></name><name><surname>Pavkov-Keller</surname><given-names>T</given-names></name><name><surname>Rathinaswamy</surname><given-names>MK</given-names></name><name><surname>Dalwadi</surname><given-names>U</given-names></name><name><surname>Yip</surname><given-names>CK</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name><name><surname>Grishin</surname><given-names>NV</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Accurate prediction of protein structures and interactions using a three-track neural network</article-title><source>Science (New York, N.Y.)</source><volume>373</volume><fpage>871</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1126/science.abj8754</pub-id><pub-id pub-id-type="pmid">34282049</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barad</surname><given-names>BA</given-names></name><name><surname>Echols</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>RY-R</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>DiMaio</surname><given-names>F</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Fraser</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy</article-title><source>Nature Methods</source><volume>12</volume><fpage>943</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3541</pub-id><pub-id pub-id-type="pmid">26280328</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulanger</surname><given-names>MJ</given-names></name><name><surname>Chow</surname><given-names>D</given-names></name><name><surname>Brevnova</surname><given-names>EE</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex</article-title><source>Science (New York, N.Y.)</source><volume>300</volume><fpage>2101</fpage><lpage>2104</lpage><pub-id pub-id-type="doi">10.1126/science.1083901</pub-id><pub-id pub-id-type="pmid">12829785</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Arendall</surname><given-names>WB</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Keedy</surname><given-names>DA</given-names></name><name><surname>Immormino</surname><given-names>RM</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Murray</surname><given-names>LW</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>MolProbity: all-atom structure validation for macromolecular crystallography</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1107/S0907444909042073</pub-id><pub-id pub-id-type="pmid">20057044</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Snow</surname><given-names>AL</given-names></name><name><surname>Rose-John</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Structure of an extracellular gp130 cytokine receptor signaling complex</article-title><source>Science (New York, N.Y.)</source><volume>291</volume><fpage>2150</fpage><lpage>2155</lpage><pub-id pub-id-type="doi">10.1126/science.1058308</pub-id><pub-id pub-id-type="pmid">11251120</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collison</surname><given-names>LW</given-names></name><name><surname>Workman</surname><given-names>CJ</given-names></name><name><surname>Kuo</surname><given-names>TT</given-names></name><name><surname>Boyd</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Vignali</surname><given-names>KM</given-names></name><name><surname>Cross</surname><given-names>R</given-names></name><name><surname>Sehy</surname><given-names>D</given-names></name><name><surname>Blumberg</surname><given-names>RS</given-names></name><name><surname>Vignali</surname><given-names>DAA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The inhibitory cytokine IL-35 contributes to regulatory T-cell function</article-title><source>Nature</source><volume>450</volume><fpage>566</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/nature06306</pub-id><pub-id pub-id-type="pmid">18033300</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Coot: model-building tools for molecular graphics</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>60</volume><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1107/S0907444904019158</pub-id><pub-id pub-id-type="pmid">15572765</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrao</surname><given-names>R</given-names></name><name><surname>Wallweber</surname><given-names>HJA</given-names></name><name><surname>Ho</surname><given-names>H</given-names></name><name><surname>Tam</surname><given-names>C</given-names></name><name><surname>Franke</surname><given-names>Y</given-names></name><name><surname>Quinn</surname><given-names>J</given-names></name><name><surname>Lupardus</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Structural Basis for Class II Cytokine Receptor Recognition by JAK1</article-title><source>Structure (London, England</source><volume>24</volume><fpage>897</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1016/j.str.2016.03.023</pub-id><pub-id pub-id-type="pmid">27133025</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>DC</given-names></name><name><surname>Fonseca-Kelly</surname><given-names>Z</given-names></name><name><surname>Cullimore</surname><given-names>ML</given-names></name><name><surname>Safabakhsh</surname><given-names>P</given-names></name><name><surname>Saris</surname><given-names>CJM</given-names></name><name><surname>Zhang</surname><given-names>GX</given-names></name><name><surname>Rostami</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Independent and interdependent immunoregulatory effects of IL-27, IFN-β, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>190</volume><fpage>3225</fpage><lpage>3234</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200141</pub-id><pub-id pub-id-type="pmid">23455508</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garbers</surname><given-names>C</given-names></name><name><surname>Spudy</surname><given-names>B</given-names></name><name><surname>Aparicio-Siegmund</surname><given-names>S</given-names></name><name><surname>Waetzig</surname><given-names>GH</given-names></name><name><surname>Sommer</surname><given-names>J</given-names></name><name><surname>Hölscher</surname><given-names>C</given-names></name><name><surname>Rose-John</surname><given-names>S</given-names></name><name><surname>Grötzinger</surname><given-names>J</given-names></name><name><surname>Lorenzen</surname><given-names>I</given-names></name><name><surname>Scheller</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>4346</fpage><lpage>4354</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.432955</pub-id><pub-id pub-id-type="pmid">23209286</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glassman</surname><given-names>CR</given-names></name><name><surname>Mathiharan</surname><given-names>YK</given-names></name><name><surname>Jude</surname><given-names>KM</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Panova</surname><given-names>O</given-names></name><name><surname>Lupardus</surname><given-names>PJ</given-names></name><name><surname>Spangler</surname><given-names>JB</given-names></name><name><surname>Ely</surname><given-names>LK</given-names></name><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Skiniotis</surname><given-names>G</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells</article-title><source>Cell</source><volume>184</volume><fpage>983</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.01.018</pub-id><pub-id pub-id-type="pmid">33606986</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glassman</surname><given-names>CR</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Majri-Morrison</surname><given-names>SS</given-names></name><name><surname>Winkelmann</surname><given-names>H</given-names></name><name><surname>Mo</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Pérez-Cruz</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>PP</given-names></name><name><surname>Koliesnik</surname><given-names>I</given-names></name><name><surname>Nagy</surname><given-names>N</given-names></name><name><surname>Hnizdilova</surname><given-names>T</given-names></name><name><surname>Picton</surname><given-names>LK</given-names></name><name><surname>Kovar</surname><given-names>M</given-names></name><name><surname>Bollyky</surname><given-names>P</given-names></name><name><surname>Steinman</surname><given-names>L</given-names></name><name><surname>Meyer</surname><given-names>E</given-names></name><name><surname>Piehler</surname><given-names>J</given-names></name><name><surname>Leonard</surname><given-names>WJ</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist</article-title><source>eLife</source><volume>10</volume><elocation-id>e65777</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.65777</pub-id><pub-id pub-id-type="pmid">34003116</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>AO</given-names></name><name><surname>Beiting</surname><given-names>DP</given-names></name><name><surname>Tato</surname><given-names>C</given-names></name><name><surname>John</surname><given-names>B</given-names></name><name><surname>Oldenhove</surname><given-names>G</given-names></name><name><surname>Lombana</surname><given-names>CG</given-names></name><name><surname>Pritchard</surname><given-names>GH</given-names></name><name><surname>Silver</surname><given-names>JS</given-names></name><name><surname>Bouladoux</surname><given-names>N</given-names></name><name><surname>Stumhofer</surname><given-names>JS</given-names></name><name><surname>Harris</surname><given-names>TH</given-names></name><name><surname>Grainger</surname><given-names>J</given-names></name><name><surname>Wojno</surname><given-names>EDT</given-names></name><name><surname>Wagage</surname><given-names>S</given-names></name><name><surname>Roos</surname><given-names>DS</given-names></name><name><surname>Scott</surname><given-names>P</given-names></name><name><surname>Turka</surname><given-names>LA</given-names></name><name><surname>Cherry</surname><given-names>S</given-names></name><name><surname>Reiner</surname><given-names>SL</given-names></name><name><surname>Cua</surname><given-names>D</given-names></name><name><surname>Belkaid</surname><given-names>Y</given-names></name><name><surname>Elloso</surname><given-names>MM</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology</article-title><source>Immunity</source><volume>37</volume><fpage>511</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.06.014</pub-id><pub-id pub-id-type="pmid">22981537</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>ML</given-names></name><name><surname>Hixon</surname><given-names>JA</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Felber</surname><given-names>BK</given-names></name><name><surname>Anver</surname><given-names>MR</given-names></name><name><surname>Stewart</surname><given-names>CA</given-names></name><name><surname>Janelsins</surname><given-names>BM</given-names></name><name><surname>Datta</surname><given-names>SK</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>McLean</surname><given-names>MH</given-names></name><name><surname>Durum</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice</article-title><source>Gastroenterology</source><volume>146</volume><fpage>210</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2013.09.060</pub-id><pub-id pub-id-type="pmid">24120477</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname><given-names>TSP</given-names></name><name><surname>Painter</surname><given-names>MW</given-names></name><collab>Immunological Genome Project Consortium</collab></person-group><year iso-8601-date="2008">2008</year><article-title>The Immunological Genome Project: networks of gene expression in immune cells</article-title><source>Nature Immunology</source><volume>9</volume><fpage>1091</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/ni1008-1091</pub-id><pub-id pub-id-type="pmid">18800157</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Kohl</surname><given-names>SAA</given-names></name><name><surname>Ballard</surname><given-names>AJ</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Romera-Paredes</surname><given-names>B</given-names></name><name><surname>Nikolov</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Adler</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>T</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Reiman</surname><given-names>D</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Zielinski</surname><given-names>M</given-names></name><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>Pacholska</surname><given-names>M</given-names></name><name><surname>Berghammer</surname><given-names>T</given-names></name><name><surname>Bodenstein</surname><given-names>S</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Vinyals</surname><given-names>O</given-names></name><name><surname>Senior</surname><given-names>AW</given-names></name><name><surname>Kavukcuoglu</surname><given-names>K</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmid">34265844</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19</article-title><source>Annual Review of Immunology</source><volume>40</volume><fpage>323</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-101220-023458</pub-id><pub-id pub-id-type="pmid">35113729</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krissinel</surname><given-names>E</given-names></name><name><surname>Henrick</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inference of macromolecular assemblies from crystalline state</article-title><source>Journal of Molecular Biology</source><volume>372</volume><fpage>774</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.05.022</pub-id><pub-id pub-id-type="pmid">17681537</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>S</given-names></name><name><surname>Ghilardi</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>de Sauvage</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms</article-title><source>PNAS</source><volume>100</volume><fpage>15047</fpage><lpage>15052</lpage><pub-id pub-id-type="doi">10.1073/pnas.2536517100</pub-id><pub-id pub-id-type="pmid">14657353</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>SJ</given-names></name><name><surname>Lacy</surname><given-names>ER</given-names></name><name><surname>Orlovsky</surname><given-names>Y</given-names></name><name><surname>Baker</surname><given-names>A</given-names></name><name><surname>Teplyakov</surname><given-names>A</given-names></name><name><surname>Obmolova</surname><given-names>G</given-names></name><name><surname>Heavner</surname><given-names>GA</given-names></name><name><surname>Richter</surname><given-names>HT</given-names></name><name><surname>Benson</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab</article-title><source>Journal of Molecular Biology</source><volume>402</volume><fpage>797</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2010.07.046</pub-id><pub-id pub-id-type="pmid">20691190</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Fabregas</surname><given-names>J</given-names></name><name><surname>Wilmes</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hafer</surname><given-names>M</given-names></name><name><surname>Pohler</surname><given-names>E</given-names></name><name><surname>Lokau</surname><given-names>J</given-names></name><name><surname>Garbers</surname><given-names>C</given-names></name><name><surname>Cozzani</surname><given-names>A</given-names></name><name><surname>Fyfe</surname><given-names>PK</given-names></name><name><surname>Piehler</surname><given-names>J</given-names></name><name><surname>Kazemian</surname><given-names>M</given-names></name><name><surname>Mitra</surname><given-names>S</given-names></name><name><surname>Moraga</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Kinetics of cytokine receptor trafficking determine signaling and functional selectivity</article-title><source>eLife</source><volume>8</volume><elocation-id>e49314</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.49314</pub-id><pub-id pub-id-type="pmid">31774398</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owaki</surname><given-names>T</given-names></name><name><surname>Asakawa</surname><given-names>M</given-names></name><name><surname>Morishima</surname><given-names>N</given-names></name><name><surname>Mizoguchi</surname><given-names>I</given-names></name><name><surname>Fukai</surname><given-names>F</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Mizuguchi</surname><given-names>J</given-names></name><name><surname>Yoshimoto</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>180</volume><fpage>2903</fpage><lpage>2911</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.5.2903</pub-id><pub-id pub-id-type="pmid">18292512</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patnaik</surname><given-names>A</given-names></name><name><surname>Morgensztern</surname><given-names>D</given-names></name><name><surname>Mantia</surname><given-names>C</given-names></name><name><surname>Tannir</surname><given-names>NM</given-names></name><name><surname>Harshman</surname><given-names>LC</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>K</given-names></name><name><surname>Chung</surname><given-names>JK</given-names></name><name><surname>Bowers</surname><given-names>B</given-names></name><name><surname>Sciaranghella</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Smith</surname><given-names>LS</given-names></name><name><surname>Naing</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors</article-title><source>Journal of Clinical Oncology</source><volume>39</volume><elocation-id>2551</elocation-id><pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.2551</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>UCSF ChimeraX: Structure visualization for researchers, educators, and developers</article-title><source>Protein Science</source><volume>30</volume><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/pro.3943</pub-id><pub-id pub-id-type="pmid">32881101</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pflanz</surname><given-names>S</given-names></name><name><surname>Timans</surname><given-names>JC</given-names></name><name><surname>Cheung</surname><given-names>J</given-names></name><name><surname>Rosales</surname><given-names>R</given-names></name><name><surname>Kanzler</surname><given-names>H</given-names></name><name><surname>Gilbert</surname><given-names>J</given-names></name><name><surname>Hibbert</surname><given-names>L</given-names></name><name><surname>Churakova</surname><given-names>T</given-names></name><name><surname>Travis</surname><given-names>M</given-names></name><name><surname>Vaisberg</surname><given-names>E</given-names></name><name><surname>Blumenschein</surname><given-names>WM</given-names></name><name><surname>Mattson</surname><given-names>JD</given-names></name><name><surname>Wagner</surname><given-names>JL</given-names></name><name><surname>To</surname><given-names>W</given-names></name><name><surname>Zurawski</surname><given-names>S</given-names></name><name><surname>McClanahan</surname><given-names>TK</given-names></name><name><surname>Gorman</surname><given-names>DM</given-names></name><name><surname>Bazan</surname><given-names>JF</given-names></name><name><surname>de Waal Malefyt</surname><given-names>R</given-names></name><name><surname>Rennick</surname><given-names>D</given-names></name><name><surname>Kastelein</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells</article-title><source>Immunity</source><volume>16</volume><fpage>779</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(02)00324-2</pub-id><pub-id pub-id-type="pmid">12121660</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pflanz</surname><given-names>S</given-names></name><name><surname>Hibbert</surname><given-names>L</given-names></name><name><surname>Mattson</surname><given-names>J</given-names></name><name><surname>Rosales</surname><given-names>R</given-names></name><name><surname>Vaisberg</surname><given-names>E</given-names></name><name><surname>Bazan</surname><given-names>JF</given-names></name><name><surname>Phillips</surname><given-names>JH</given-names></name><name><surname>McClanahan</surname><given-names>TK</given-names></name><name><surname>de Waal Malefyt</surname><given-names>R</given-names></name><name><surname>Kastelein</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>172</volume><fpage>2225</fpage><lpage>2231</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.4.2225</pub-id><pub-id pub-id-type="pmid">14764690</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradhan</surname><given-names>A</given-names></name><name><surname>Lambert</surname><given-names>QT</given-names></name><name><surname>Griner</surname><given-names>LN</given-names></name><name><surname>Reuther</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Activation of JAK2-V617F by components of heterodimeric cytokine receptors</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>16651</fpage><lpage>16663</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.071191</pub-id><pub-id pub-id-type="pmid">20363735</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname><given-names>A</given-names></name><name><surname>Rubinstein</surname><given-names>JL</given-names></name><name><surname>Fleet</surname><given-names>DJ</given-names></name><name><surname>Brubaker</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination</article-title><source>Nature Methods</source><volume>14</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4169</pub-id><pub-id pub-id-type="pmid">28165473</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Fleet</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction</article-title><source>Nature Methods</source><volume>17</volume><fpage>1214</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1038/s41592-020-00990-8</pub-id><pub-id pub-id-type="pmid">33257830</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Garcia</surname><given-names>R</given-names></name><name><surname>Gomez-Blanco</surname><given-names>J</given-names></name><name><surname>Cuervo</surname><given-names>A</given-names></name><name><surname>Carazo</surname><given-names>JM</given-names></name><name><surname>Sorzano</surname><given-names>COS</given-names></name><name><surname>Vargas</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>DeepEMhancer: a deep learning solution for cryo-EM volume post-processing</article-title><source>Communications Biology</source><volume>4</volume><elocation-id>874</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-021-02399-1</pub-id><pub-id pub-id-type="pmid">34267316</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxton</surname><given-names>RA</given-names></name><name><surname>Tsutsumi</surname><given-names>N</given-names></name><name><surname>Su</surname><given-names>LL</given-names></name><name><surname>Abhiraman</surname><given-names>GC</given-names></name><name><surname>Mohan</surname><given-names>K</given-names></name><name><surname>Henneberg</surname><given-names>LT</given-names></name><name><surname>Aduri</surname><given-names>NG</given-names></name><name><surname>Gati</surname><given-names>C</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10</article-title><source>Science (New York, N.Y.)</source><volume>371</volume><elocation-id>eabc8433</elocation-id><pub-id pub-id-type="doi">10.1126/science.abc8433</pub-id><pub-id pub-id-type="pmid">33737461</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skiniotis</surname><given-names>G</given-names></name><name><surname>Lupardus</surname><given-names>PJ</given-names></name><name><surname>Martick</surname><given-names>M</given-names></name><name><surname>Walz</surname><given-names>T</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex</article-title><source>Molecular Cell</source><volume>31</volume><fpage>737</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2008.08.011</pub-id><pub-id pub-id-type="pmid">18775332</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spangler</surname><given-names>JB</given-names></name><name><surname>Moraga</surname><given-names>I</given-names></name><name><surname>Mendoza</surname><given-names>JL</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Insights into cytokine-receptor interactions from cytokine engineering</article-title><source>Annual Review of Immunology</source><volume>33</volume><fpage>139</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120211</pub-id><pub-id pub-id-type="pmid">25493332</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stumhofer</surname><given-names>JS</given-names></name><name><surname>Laurence</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>EH</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Tato</surname><given-names>CM</given-names></name><name><surname>Johnson</surname><given-names>LM</given-names></name><name><surname>Villarino</surname><given-names>AV</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Yoshimura</surname><given-names>A</given-names></name><name><surname>Sehy</surname><given-names>D</given-names></name><name><surname>Saris</surname><given-names>CJM</given-names></name><name><surname>O’Shea</surname><given-names>JJ</given-names></name><name><surname>Hennighausen</surname><given-names>L</given-names></name><name><surname>Ernst</surname><given-names>M</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system</article-title><source>Nature Immunology</source><volume>7</volume><fpage>937</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1038/ni1376</pub-id><pub-id pub-id-type="pmid">16906166</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stumhofer</surname><given-names>JS</given-names></name><name><surname>Silver</surname><given-names>JS</given-names></name><name><surname>Laurence</surname><given-names>A</given-names></name><name><surname>Porrett</surname><given-names>PM</given-names></name><name><surname>Harris</surname><given-names>TH</given-names></name><name><surname>Turka</surname><given-names>LA</given-names></name><name><surname>Ernst</surname><given-names>M</given-names></name><name><surname>Saris</surname><given-names>CJM</given-names></name><name><surname>O’Shea</surname><given-names>JJ</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10</article-title><source>Nature Immunology</source><volume>8</volume><fpage>1363</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1038/ni1537</pub-id><pub-id pub-id-type="pmid">17994025</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stumhofer</surname><given-names>JS</given-names></name><name><surname>Tait</surname><given-names>ED</given-names></name><name><surname>Quinn</surname><given-names>WJ</given-names></name><name><surname>Hosken</surname><given-names>N</given-names></name><name><surname>Spudy</surname><given-names>B</given-names></name><name><surname>Goenka</surname><given-names>R</given-names></name><name><surname>Fielding</surname><given-names>CA</given-names></name><name><surname>O’Hara</surname><given-names>AC</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Jones</surname><given-names>ML</given-names></name><name><surname>Saris</surname><given-names>CJM</given-names></name><name><surname>Rose-John</surname><given-names>S</given-names></name><name><surname>Cua</surname><given-names>DJ</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Elloso</surname><given-names>MM</given-names></name><name><surname>Grötzinger</surname><given-names>J</given-names></name><name><surname>Cancro</surname><given-names>MP</given-names></name><name><surname>Levin</surname><given-names>SD</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A role for IL-27p28 as an antagonist of gp130-mediated signaling</article-title><source>Nature Immunology</source><volume>11</volume><fpage>1119</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1038/ni.1957</pub-id><pub-id pub-id-type="pmid">21057510</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tait Wojno</surname><given-names>ED</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name><name><surname>Stumhofer</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Immunobiology of the Interleukin-12 Family: Room for Discovery</article-title><source>Immunity</source><volume>50</volume><fpage>851</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.011</pub-id><pub-id pub-id-type="pmid">30995503</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Pflanz</surname><given-names>S</given-names></name><name><surname>Kastelein</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses</article-title><source>Immunity</source><volume>19</volume><fpage>641</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(03)00296-6</pub-id><pub-id pub-id-type="pmid">14614851</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villarino</surname><given-names>AV</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Saris</surname><given-names>CJM</given-names></name><name><surname>Caton</surname><given-names>AJ</given-names></name><name><surname>Lucas</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>T</given-names></name><name><surname>de Sauvage</surname><given-names>FJ</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Positive and negative regulation of the IL-27 receptor during lymphoid cell activation</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>174</volume><fpage>7684</fpage><lpage>7691</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.12.7684</pub-id><pub-id pub-id-type="pmid">15944269</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>RX</given-names></name><name><surname>Yu</surname><given-names>CR</given-names></name><name><surname>Mahdi</surname><given-names>RM</given-names></name><name><surname>Egwuagu</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>36012</fpage><lpage>36021</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.390625</pub-id><pub-id pub-id-type="pmid">22936807</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Hou</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Egwuagu</surname><given-names>CE</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice</article-title><source>European Journal of Immunology</source><volume>46</volume><fpage>1343</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1002/eji.201546095</pub-id><pub-id pub-id-type="pmid">27019190</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilmes</surname><given-names>S</given-names></name><name><surname>Jeffrey</surname><given-names>P-A</given-names></name><name><surname>Martinez-Fabregas</surname><given-names>J</given-names></name><name><surname>Hafer</surname><given-names>M</given-names></name><name><surname>Fyfe</surname><given-names>PK</given-names></name><name><surname>Pohler</surname><given-names>E</given-names></name><name><surname>Gaggero</surname><given-names>S</given-names></name><name><surname>López-García</surname><given-names>M</given-names></name><name><surname>Lythe</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Guerrier</surname><given-names>T</given-names></name><name><surname>Launay</surname><given-names>D</given-names></name><name><surname>Mitra</surname><given-names>S</given-names></name><name><surname>Piehler</surname><given-names>J</given-names></name><name><surname>Molina-París</surname><given-names>C</given-names></name><name><surname>Moraga</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses</article-title><source>eLife</source><volume>10</volume><elocation-id>e66014</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.66014</pub-id><pub-id pub-id-type="pmid">33871355</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78463.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kruse</surname><given-names>Andrew C</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard Medical School</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2022.03.08.483525" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.08.483525"/></front-stub><body><p>Cytokines are small protein signaling molecules with a diverse range of activities in inflammation and immune system function. This manuscript reports the cryo-EM structure of the cytokine interleukin-27 (IL-27) bound to soluble domains of two receptor subunits, IL-27Rα and gp130. IL-27 is a composite cytokine consisting of the protein p28 bound to EBI3, which resembles soluble cytokine receptors such as the receptors for IL-6, IL-11 or CNTF. IL-27 signals predominantly via STAT1 and plays an important role in immune homeostasis. The data provide a detailed molecular view of how IL-27 binds to its receptor.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78463.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kruse</surname><given-names>Andrew C</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard Medical School</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.08.483525">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.03.08.483525v2">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Structure of the IL-27 quaternary receptor signaling complex&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Volker Dötsch as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Please address the points raised by reviewers regarding clarity and presentation as well as referencing and discussion of some prior work. No additional data is required in a revised manuscript.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>In the opening paragraph of the introduction the authors indicate that when cytokines bind their receptors this leads to the activation of JAK-STAT signaling. While that is the case for the cytokines discussed here, it is not a general characteristic of all cytokines, which is how this statement currently reads.</p><p>Also, given the way that the two receptor subunits bend to facilitate binding of IL-27, it would be useful to see how these domains connect to the rest of the receptor domains on the surface of the plasma membrane to give a better visual of the overall interaction of IL-27 with the membrane bound receptor. The authors provided a figure such as this in their similar paper describing the interaction of IL-6 with its receptor (Boulanger et al., Science 2003). A figure or an additional figure panel such as this would also be useful to the reader here.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>This first structure of the complex of the heterodimeric cytokine IL-27 bound to the extracellular portions of the two receptor subunits gp130 and WSX-1 is very interesting and will be a major breakthrough on the way to fully understand the structural plasticity of cytokines and their cognate receptor complexes. EBI3 is part of the cytokines IL-27, IL-35 and IL-39. P28 has been shown to signal via EBI3 and via the IL-6R, which interestingly results in different receptor complexes and different intracellular signals. To fully explain this structural plasticity, a higher resolution structure will be required, which can be expected in the future.</p><p>There are some points the authors might want to address.</p><p>1. The author state that the receptor protein is mainly expressed on T-cells and NK cells. This is not fully correct since WSX-1 is also expressed on monocytic cells, dendritic cells, B-cells, endothelial cells and some epithelial cells. This should be corrected.</p><p>2. The authors describe that the complex of IL-27 and the two receptor proteins was made possible by covalently fusing p28 to gp130. Some more details and a scheme should be given to illustrate this approach. The authors argue that the linker did not constrain the binding mode. The experiments on which this statement was based should be shown in the supplemental material.</p><p>3. Along the same line: the authors state that the site 3 binding between p28 and the D1 domain of gp130 is similar to the site 3 binding of human or viral IL-6. In the case of IL-6, however, it has been demonstrated that the NH2-terminus of gp130 inserts and interacts with the tip of the cytokine. Is such an interaction also possible for p28 and would such an interaction be hindered by the covalent linker? This point should be mentioned and discussed.</p><p>4. EBI3 is part of the cytokines IL-27, IL-35 and IL-39. P28 has been shown to signal via EBI3 and via the IL-6R, which interestingly results in different receptor complexes and different intracellular signals. This should at least be mentioned (and cited) in the discussion and the problem of structural plasticity should be explained to the reader.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Suggestion: use the term 'local resolution' instead of 'localized resolution'.</p><p>line 89: 'electron density is not the correct term for maps determined using cryoEM. use 'cryoEM density or 'density'.</p><p>Figure 1:</p><p>It would be useful if the schematic in panel A had the proteins arranged with their binding interfaces oriented in the way that would be to interact with each other in the tetrameric complex.</p><p>Figure S1:</p><p>A: What part of the map is locally refined (and why)? Showing the mask(s) used would be helpful.</p><p>Figure S2: make the boxes in panel A more representative (i.e. squares) of the zoom-in area in panels B-D.</p><p>Map + Model:</p><p>When the map is deposited, it is requested that an unsharpened map is deposited in addition to the DeepEMhancer sharped map since CNNs trained like this could potentially invent misleading protein features (and since it is trained on real protein features, unlike previous generation sharpening algos, the 'fake' features will look 'real').</p><p>I don't think the density in the provided structure supports a polyE helix in p28. Maybe it should not be modeled?</p><p>The map used to estimate local resolution in figure S1B should not be the DeepEMhancer-sharped (maybe it is not, but unclear from the text which map was used, and I'm surprised that the local resolution is estimated to be so similar in different areas).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.78463.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>In the opening paragraph of the introduction the authors indicate that when cytokines bind their receptors this leads to the activation of JAK-STAT signaling. While that is the case for the cytokines discussed here, it is not a general characteristic of all cytokines, which is how this statement currently reads.</p></disp-quote><p>We have adjusted this statement to read:</p><p>“Binding of cytokines to cell surface receptors, in most cases, leads to activation of receptor-associated Janus Kinase (JAK) proteins which phosphorylate each other as well as downstream Signal Transducer and Activator of Transcription (STAT) proteins, triggering nuclear translocation and regulation of gene expression.”</p><disp-quote content-type="editor-comment"><p>Also, given the way that the two receptor subunits bend to facilitate binding of IL-27, it would be useful to see how these domains connect to the rest of the receptor domains on the surface of the plasma membrane to give a better visual of the overall interaction of IL-27 with the membrane bound receptor. The authors provided a figure such as this in their similar paper describing the interaction of IL-6 with its receptor (Boulanger et al., Science 2003). A figure or an additional figure panel such as this would also be useful to the reader here.</p></disp-quote><p>We have added a panel to Figure 1.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>This first structure of the complex of the heterodimeric cytokine IL-27 bound to the extracellular portions of the two receptor subunits gp130 and WSX-1 is very interesting and will be a major breakthrough on the way to fully understand the structural plasticity of cytokines and their cognate receptor complexes. EBI3 is part of the cytokines IL-27, IL-35 and IL-39. P28 has been shown to signal via EBI3 and via the IL-6R, which interestingly results in different receptor complexes and different intracellular signals. To fully explain this structural plasticity, a higher resolution structure will be required, which can be expected in the future.</p><p>There are some points the authors might want to address.</p><p>1. The author state that the receptor protein is mainly expressed on T-cells and NK cells. This is not fully correct since WSX-1 is also expressed on monocytic cells, dendritic cells, B-cells, endothelial cells and some epithelial cells. This should be corrected.</p></disp-quote><p>We have updated the text which now reads:</p><p>“IL-27 signals through a receptor complex consisting of IL-27Rα (TCCR/WSX-1) and gp130 expressed on T cells, NK cells, monocytes, dendritic cells, B cells as well as subsets of endothelial and epithelial cells”</p><disp-quote content-type="editor-comment"><p>2. The authors describe that the complex of IL-27 and the two receptor proteins was made possible by covalently fusing p28 to gp130. Some more details and a scheme should be given to illustrate this approach. The authors argue that the linker did not constrain the binding mode. The experiments on which this statement was based should be shown in the supplemental material.</p></disp-quote><p>We have adjusted the description of this as follows:</p><p>“Importantly, the long linker did not constrain the binding mode, with ~110 Å of unresolved residues spanning a distance of 38 Å between termini (Figure 1 – Supplement 3), but rather raised the effective concentration of gp130.” And added an additional figure supplement to Figure 1 (Figure 1 – supplement 3).</p><disp-quote content-type="editor-comment"><p>3. Along the same line: the authors state that the site 3 binding between p28 and the D1 domain of gp130 is similar to the site 3 binding of human or viral IL-6. In the case of IL-6, however, it has been demonstrated that the NH2-terminus of gp130 inserts and interacts with the tip of the cytokine. Is such an interaction also possible for p28 and would such an interaction be hindered by the covalent linker? This point should be mentioned and discussed.</p></disp-quote><p>We have elaborated on the placement of the AB loop to include discussion of the N-terminus of gp130, as follows:</p><p>“The site 3 interaction is extended by the AB loop of p28 which contacts both gp130 and Ebi3. We do not observe an interaction between the N-terminus of gp130 and helix D of the four-helix bundle as observed for other site 3 interactions, however, this may be due to the use of a flexible GS linker which connects p28 to gp130.”</p><disp-quote content-type="editor-comment"><p>4. EBI3 is part of the cytokines IL-27, IL-35 and IL-39. P28 has been shown to signal via EBI3 and via the IL-6R, which interestingly results in different receptor complexes and different intracellular signals. This should at least be mentioned (and cited) in the discussion and the problem of structural plasticity should be explained to the reader.</p></disp-quote><p>A paragraph discussing alternative heterodimeric cytokines has been added to the discussion:</p><p>“In addition to their roles in IL-27 signaling, p28 and Ebi3 have been implicated in the assembly of alternate cytokine complexes. Ebi3 has been reported to complex with the p35 subunit of IL-12 to form IL-35 (Collison et al., 2007) and the p19 subunit of IL-23 to form IL-39 (Wang et al., 2016) while p28 has been proposed to interact with IL-6Rα (Garbers et al., 2013) and the p40 subunit of IL-12/23 (Wang et al., 2012). These results suggest structural plasticity among heterodimeric cytokines, however, additional work is needed to characterize the physiological relevance and biochemical basis for these cytokines.”</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Suggestion: use the term 'local resolution' instead of 'localized resolution'.</p><p>line 89: 'electron density is not the correct term for maps determined using cryoEM. use 'cryoEM density or 'density'.</p></disp-quote><p>We have changed all instances of “localised resolution” to “local resolution” and all instances of “electron density” to “density”</p><disp-quote content-type="editor-comment"><p>Figure 1:</p><p>It would be useful if the schematic in panel A had the proteins arranged with their binding interfaces oriented in the way that would be to interact with each other in the tetrameric complex.</p></disp-quote><p>We have adjusted the orientation of the proteins in F1A.</p><disp-quote content-type="editor-comment"><p>Figure S1:</p><p>A: What part of the map is locally refined (and why)? Showing the mask(s) used would be helpful.</p></disp-quote><p>Alignment including the D3 domain of gp130 resulted in poorer global resolutions, so the complex was locally refined with a mask excluding this domain. The mask is now depicted in Figure 1 – supplement 1. We have clarified this as follows in the methods:</p><p>“These particles were refined using cryoSPARC non-uniform refinement (Punjani et al., 2020) followed by local refinement with a mask excluding gp130 D3 domain to achieve a resolution of 3.47 Å.”</p><disp-quote content-type="editor-comment"><p>Figure S2: make the boxes in panel A more representative (i.e. squares) of the zoom-in area in panels B-D.</p></disp-quote><p>We have adjusted the boxes to be more representative of the zoom-in regions.</p><disp-quote content-type="editor-comment"><p>Map + Model:</p><p>When the map is deposited, it is requested that an unsharpened map is deposited in addition to the DeepEMhancer sharped map since CNNs trained like this could potentially invent misleading protein features (and since it is trained on real protein features, unlike previous generation sharpening algos, the 'fake' features will look 'real').</p></disp-quote><p>We have deposited the map with both unsharpened half-maps.</p><disp-quote content-type="editor-comment"><p>I don't think the density in the provided structure supports a polyE helix in p28. Maybe it should not be modeled?</p></disp-quote><p>We agree that the density is weaker in the region of the polyE helix, likely due to local flexibility. We have adjusted our description of the polyE region and its interaction to account for this uncertainty:</p><p>“One notable feature of this interface is the contribution of a 13 amino acid polyglutamic acid region in p28. This region is not well observed in the cryoEM density, but may form an α helix (polyE helix) and contact R74 and K77 in the IL-27Rɑ D1 domain.”</p><disp-quote content-type="editor-comment"><p>The map used to estimate local resolution in figure S1B should not be the DeepEMhancer-sharped (maybe it is not, but unclear from the text which map was used, and I'm surprised that the local resolution is estimated to be so similar in different areas).</p></disp-quote><p>The map presented was the DeepEMhanced map, the figure is now changed to have the globally sharpened map for the local resolution estimation. As well, the gradient range used to color the map has been adjusted to better depict the values present.</p></body></sub-article></article>